APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

15 11 2021 16:01:00 提供 Nasdaq GlobeNewswire

Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback

12 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting

10 11 2021 07:00:04 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results

08 11 2021 16:01:00 提供 Nasdaq GlobeNewswire

Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting

04 11 2021 09:17:31 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

03 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results

01 11 2021 07:00:00 提供 Nasdaq GlobeNewswire

Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH

15 10 2021 07:17:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 10 2021 16:05:00 提供 Nasdaq GlobeNewswire

Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting

30 9 2021 11:49:32 提供 Nasdaq GlobeNewswire